Cross‐Talk Between Histamine H 2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Valeria Torralba-Agu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Air…. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Leukemia, Myeloid, Acute, Receptors, Histamine H2, Receptor Cross-Talk. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Buenos Aires, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación.
Abstract (Originalsprache)
This study investigates the impact of histamine H 2 receptor activation on glucocorticoid receptor (GR)‐mediated transcriptional activity, as well as its effects on leukemic cell proliferation and chemotherapy resistance. We demonstrate that activation of the histamine H 2 receptor by its specific agonist, amthamine, enhances GR transcriptional activity induced by dexamethasone in both artificial promoter‐driven luciferase reporter assays and endogenous GR‐responsive genes. Mechanistically, histamine H 2 receptor signaling exerts a dual regulatory effect: an inhibitory influence mediated by cAMP and a stimulatory effect through inhibition of the PI3K‐AKT–mTOR‐S6K pathway and activation of the ERK pathway. Furthermore, while dexamethasone reduces leukemic cell proliferation at high doses, it increases it at lower concentrations, an effect that is abrogated by amthamine. Moreover, the combination of the glucocorticoid and the H 2 agonist reestablishes leukemic cell sensitivity to cytarabine, thereby restoring its cytotoxicity. Together, these findings offer insight into the molecular mechanisms and therapeutic potential of the interplay between histamine H 2 ligands and GR agonists, and may help guide dosage optimization and mitigate the well‐known side effects of glucocorticoid therapy, with potential clinical implications for the treatment of acute myeloid leukemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Buenos Aires, Argentina.
- Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
- Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina.
ORCID-Profile: Valeria Torralba-Agu, Natalia Fernández, C Daniel Zappia, Federico Monczor
Förderung
- Universidad de Buenos Aires
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
Zitieren
APA
Torralba-Agu, V., Fernández, N., Shayo, C., Davio, C., Zappia, C. D., & Monczor, F. (2026). Cross‐Talk Between Histamine H 2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70314
Vancouver
Torralba-Agu V, Fernández N, Shayo C, Davio C, Zappia CD, Monczor F. Cross‐Talk Between Histamine H 2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70314
BibTeX
@article{TorralbaAgu2026,
author = {Torralba-Agu, Valeria and Fernández, Natalia and Shayo, Carina and Davio, Carlos and Zappia, C Daniel and Monczor, Federico},
title = {Cross‐Talk Between Histamine H 2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70314}
}
EUVIMED